AbbVie
Baxter to split in two next year
March 28, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, Abbott, baxter, biopharma, gambro
Baxter is taking a plunge into the world of restructuring by splitting into two entities: one which is yet to …
Major new launches for 2014
March 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AbbVie, Big Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, ask, johnson, lilly, top 10
AbbVie AbbVie needs a blockbuster to eventually replace its flagship Humira – and is hoping its new hepatitis C treatments …
AbbVie expands into Singapore
February 10, 2014Manufacturing and Production, Sales and Marketing AbbVie, Abbott, Asia, Cancer, Singapore, oncology
AbbVie is expanding its manufacturing operation into Asia for the first time with a $320 million investment in a new …
AbbVie ‘pleased’ with first year
February 3, 2014Sales and Marketing AbbVie, Abbott, CLL, EMA, HIV, Humira
Rheumatoid arthritis treatment Humira – as expected – has driven AbbVie in its first year as a standalone company, accounting …
Servier signs cancer partnership
January 29, 2014Research and Development, Sales and Marketing AbbVie, Servier, breast cancer, curie
Servier has extended by three years its deal with leading research group Curie-Cancer to identify therapeutic targets for treating triple-negative …
AbbVie advances oncology drug
January 21, 2014Research and Development, Sales and Marketing AbbVie, DNA, oncology, veliparib
AbbVie has begun a Phase III trial of its investigational compound veliparib in women with early-stage, triple-negative breast cancer. This …
AbbVie posts strong results for Hep C pill
December 11, 2013Research and Development, Sales and Marketing 3D, AbbVie, FDA, Gilead, hep C
AbbVie’s investigational hepatitis C pill cured 96% of difficult-to-treat patients in a late-stage clinical trial and looks set to muscle …
CLL drug achieves ‘unprecedented’ remissions
December 9, 2013Research and Development, Sales and Marketing AbbVie, CML, Genentech, abt-199
AbbVie and Genentech’s investigational oncology drug ABT-199 has performed well in a Phase I trial for blood cancer, according to …
Court annuls EMA data decision
December 5, 2013Medical Communications, Sales and Marketing AbbVie, EMA, Goldacre, InterMune, alltrials, transparency
The European Court of Justice has annulled interim injunctions against the European Medicines Agency issued earlier this year after AbbVie …
Robert Brooks joins Achilles from Abbott
September 10, 2013Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Abbott, achilles, brook
Supply chain firm Achilles has hired Dr Robert Brooks to be a Business Development director from pharma firm Abbott. Brooks …
Marginal sales increase for Abbott
July 18, 2013Sales and Marketing AbbVie, Abbott, Q2
Abbott’s second quarter results saw the company buffeted by currency exchange issues – primarily the yen weakening against the US …
Orencia matches Humira
June 13, 2013Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA
Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …
AbbVie and Galapagos extend deal
May 21, 2013Sales and Marketing AbbVie, Crohn's, Galapagos
AbbVie and Belgian biotech Galapagos have bolted on a development programme for Crohn’s disease to the selective JAK1 inhibitor they …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
